These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37238630)

  • 1. Homogeneous, Synthetic, Non-Saccharide Glycosaminoglycan Mimetics as Potent Inhibitors of Human Cathepsin G.
    Afosah DK; Fayyad RM; Puliafico VR; Merrell S; Langmia EK; Diagne SR; Al-Horani RA; Desai UR
    Biomolecules; 2023 Apr; 13(5):. PubMed ID: 37238630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin-like dextran derivatives as well as glycosaminoglycans inhibit the enzymatic activity of human cathepsin G.
    Ledoux D; Merciris D; Barritault D; Caruelle JP
    FEBS Lett; 2003 Feb; 537(1-3):23-9. PubMed ID: 12606025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulphated penta-galloyl glucopyranoside (SPGG) is glycosaminoglycan mimetic allosteric inhibitor of cathepsin G.
    Al-Horani RA; Afosah DK; Kar S; Aliter KF; Mottamal M
    RPS Pharm Pharmacol Rep; 2023 Jan; 2(1):rqad001. PubMed ID: 36844783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent, Selective, Allosteric Inhibition of Human Plasmin by Sulfated Non-Saccharide Glycosaminoglycan Mimetics.
    Afosah DK; Al-Horani RA; Sankaranarayanan NV; Desai UR
    J Med Chem; 2017 Jan; 60(2):641-657. PubMed ID: 27976897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substituted 4H-3,1-benzoxazine-4-one Derivatives as Inhibitors of Cathepsin G.
    Aliter KF; Al-Horani RA
    Med Chem; 2024; 20(10):944-949. PubMed ID: 38676528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the human leukocyte endopeptidases elastase and cathepsin G and of porcine pancreatic elastase by N-oleoyl derivatives of heparin.
    Baici A; Diczházi C; Neszmélyi A; Móczár E; Hornebeck W
    Biochem Pharmacol; 1993 Nov; 46(9):1545-9. PubMed ID: 8240409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincense.
    Tausch L; Henkel A; Siemoneit U; Poeckel D; Kather N; Franke L; Hofmann B; Schneider G; Angioni C; Geisslinger G; Skarke C; Holtmeier W; Beckhaus T; Karas M; Jauch J; Werz O
    J Immunol; 2009 Sep; 183(5):3433-42. PubMed ID: 19648270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric Inhibition of Factor XIIIa. Non-Saccharide Glycosaminoglycan Mimetics, but Not Glycosaminoglycans, Exhibit Promising Inhibition Profile.
    Al-Horani RA; Karuturi R; Lee M; Afosah DK; Desai UR
    PLoS One; 2016; 11(7):e0160189. PubMed ID: 27467511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Arylacyl O-sulfonated aminoglycosides as novel inhibitors of human neutrophil elastase, cathepsin G and proteinase 3.
    Craciun I; Fenner AM; Kerns RJ
    Glycobiology; 2016 Jul; 26(7):701-709. PubMed ID: 26850997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of heparin cofactor II with neutrophil elastase and cathepsin G.
    Pratt CW; Tobin RB; Church FC
    J Biol Chem; 1990 Apr; 265(11):6092-7. PubMed ID: 2318847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of low-molecular-weight semi-synthetic sulfated heparins with human leukocyte elastase and human Cathepsin G.
    Sissi C; Lucatello L; Naggi A; Torri G; Palumbo M
    Biochem Pharmacol; 2006 Jan; 71(3):287-93. PubMed ID: 16310171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease.
    Voynow JA; Zheng S; Kummarapurugu AB
    Front Pharmacol; 2020; 11():1011. PubMed ID: 32733248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of cathepsin G: a patent review (2005 to present).
    Kosikowska P; Lesner A
    Expert Opin Ther Pat; 2013 Dec; 23(12):1611-24. PubMed ID: 24079661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Masking of a cathepsin G cleavage site in vivo contributes to the proteolytic resistance of major histocompatibility complex class II molecules.
    Burster T; Macmillan H; Hou T; Schilling J; Truong P; Boehm BO; Zou F; Lau K; Strohman M; Schaffert S; Busch R; Mellins ED
    Immunology; 2010 Jul; 130(3):436-46. PubMed ID: 20331476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cathepsin G Inhibition by Serpinb1 and Serpinb6 Prevents Programmed Necrosis in Neutrophils and Monocytes and Reduces GSDMD-Driven Inflammation.
    Burgener SS; Leborgne NGF; Snipas SJ; Salvesen GS; Bird PI; Benarafa C
    Cell Rep; 2019 Jun; 27(12):3646-3656.e5. PubMed ID: 31216481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulfonated Nonsaccharide Heparin Mimetics Are Potent and Noncompetitive Inhibitors of Human Neutrophil Elastase.
    Al-Horani RA; Aliter KF; Kar S; Mottamal M
    ACS Omega; 2021 May; 6(19):12699-12710. PubMed ID: 34056422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the Process of Discovering Leads That Target the Heparin-Binding Site of Neutrophil Elastase in the Sputum of Cystic Fibrosis Patients.
    Morla S; Sankaranarayanan NV; Afosah DK; Kumar M; Kummarapurugu AB; Voynow JA; Desai UR
    J Med Chem; 2019 Jun; 62(11):5501-5511. PubMed ID: 31074986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of neutrophil cathepsin G by oxidized mucus proteinase inhibitor. Effect of heparin.
    Boudier C; Cadène M; Bieth JG
    Biochemistry; 1999 Jun; 38(26):8451-7. PubMed ID: 10387091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil cathepsin G proteolysis of protease-activated receptor 4 generates a novel, functional tethered ligand.
    Stoller ML; Basak I; Denorme F; Rowley JW; Alsobrooks J; Parsawar K; Nieman MT; Yost CC; Hamilton JR; Bray PF; Campbell RA
    Blood Adv; 2022 Apr; 6(7):2303-2308. PubMed ID: 34883511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of specific cell permeable cathepsin G inhibitors resulted in reduced antigen processing in primary dendritic cells.
    Reich M; Lesner A; Legowska A; Sieńczyk M; Oleksyszyn J; Boehm BO; Burster T
    Mol Immunol; 2009 Sep; 46(15):2994-9. PubMed ID: 19615749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.